Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Varsha Gandhi, PhD, on Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Sep
29
Today In Oncology
Cancer Statistics 2026: What Every Medical Oncologist Should Know
New Prognostic Model May Improve Risk Classification in Metastatic Clear Cell RCC
Adding Targeted Immunotherapy to Pembrolizumab in Recurrent or Metastatic HPV16-Positive Head and Neck Squamous Cell Carcinoma
SRS Is a Reasonable Option for Patients With SCLC and Brain Metastases
Fractionated SRS Approach Improves Outcomes for Patients With Resected Large Brain Metastases
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo